APYX

Rating neutralAI Memo

Apyx Medical

As of 2026-09-03/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 beat and higher FY2026 outlook • 2026-08-06

Base target: $4 / p=50% prob

Biggest risk

The company remains loss-making, OEM revenue declined 12%, and the post-earnings share reaction was negative despite the beat. Low coverage and small-cap execution risk make a durable re-rating unproven.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

Q2 revenue and EPS beat expectations, Surgical Aesthetics grew 28%, gross margin improved, and management reaffirmed a higher FY2026 revenue range. Successful PowerLipo adoption could support further AYON-led growth. [#SEC-8K-2026-08-06]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-03

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q3 margin and adoption execution check
Sustained AYON-led mix shift
Q2 revenue and EPS beat expectations, Surgical Aesthetics grew 28%, gross margin improved, and management reaffirmed a higher FY2026 revenue range.

BearKey bullets

AYON and PowerLipo adoption may not scale as expected.
Early PowerLipo manufacturing costs could pressure second-half margins.
Low analyst coverage and limited independent estimate history reduce confidence in valuation signals.

WatchKey bullets

Q2 beat and higher FY2026 outlook

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $4 (p=50%)

Target spread vs base: +65% / -55%

Scenario probabilities

Bull Target: $7 (p=25%)Base Target: $4 (p=50%)Bear Target: $2 (p=25%)

Commentary

Primary operating evidence is constructive, but coverage is sparse. Investing.com reported Q2 EPS of -$0.07 versus -$0.09 expected and revenue of $13.9 million versus $13.32 million expected, yet shares fell 4.81% after hours and the Sep. 2 anchor of $3.08 remained below the $4.16 pre-release close (https://www.investing.com/equities/bovie-medical-corp-earnings). The mixed reaction and absent social data support monitoring rather than a high-conviction bullish stance.

As of 2026-09-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q3 margin and adoption execution check
Sustained AYON-led mix shift

Scenarios

Bull Target (Scenario probability)

$7 / p=25% prob

Base Target (Scenario probability)

$4 / p=50% prob

Bear Target (Scenario probability)

$2 / p=25% prob

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.62

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
Q2 beat and higher FY2026 outlook
The company reported Q2 revenue of $13.9 million, up 22%, Surgical Aesthetics growth of 28%, a narrower adjusted EBITDA loss of $0.7 million, and reaffirmed FY2026 revenue guidance of $59-$60 million. This is above the prior $57.5-$58.5 million baseline. [#SEC-8K-2026-08-06] [#8-K-2026-03-10]
Prob 100.00% • Move 8.00% • Priced-in 80.00%
EVENT2026-09-30
AYON PowerLipo commercial rollout
Apyx received expanded FDA 510(k) clearance and began a limited launch of the reusable power-liposuction handpiece, with broader Q3 rollout the next adoption test. [#SEC-8K-2026-08-06]
Prob 70.00% • Move 18.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Q3 margin and adoption execution check
2026-11-05
Persistent losses, planned OEM decline, and possible near-term margin pressure from scaling new PowerLipo units create downside risk if Q3 adoption or gross-margin progression disappoints. [#SEC-8K-2026-08-06]
Prob 45% • Move -18% • Priced-in 55%

Long-term Catalysts

Months to a year

Sustained AYON-led mix shift
2026-12-31
The long thesis depends on continued AYON placements, utilization, and handpiece demand sustaining Surgical Aesthetics growth while offsetting planned OEM contraction. [#SEC-8K-2026-08-06] [#10-K-2026-03-10]
Prob 55% • Move 25% • Priced-in 45%

Risks

AYON and PowerLipo adoption may not scale as expected.
Early PowerLipo manufacturing costs could pressure second-half margins.
Low analyst coverage and limited independent estimate history reduce confidence in valuation signals.
OEM contraction may reduce diversification while Surgical Aesthetics carries more of the growth burden. [#SEC-8K-2026-08-06]
The company remains loss-making and requires continued execution to improve operating leverage.

Peers

Symbol	Summary
BHC	Closest read-through because Apyx identifies Bausch Health's Solta Medical as a major liposuction competitor; still an imperfect comp because BHC is much larger and diversified. [#10-K-2026-03-10]
BSX	Broad medtech commercialization and execution benchmark, but not a direct aesthetics competitor.
EW	Scaled medtech benchmark for durability, margins, and balance-sheet quality; valuation comparison is loose.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-03

Loading AI feed…

Symbol

Summary

BHC

Closest read-through because Apyx identifies Bausch Health's Solta Medical as a major liposuction competitor; still an imperfect comp because BHC is much larger and diversified. [#10-K-2026-03-10]

BSX

Broad medtech commercialization and execution benchmark, but not a direct aesthetics competitor.

Scaled medtech benchmark for durability, margins, and balance-sheet quality; valuation comparison is loose.